You are here
47th European Association for the Study of the Liver (EASL)/The International Liver Conference
High-efficacy results from non–interferon-based therapies for hepatitis C virus (HCV) dominated the discussion at the EASL meeting, leading to widespread talk of a new era emerging in treatment. Also notable among the research presented were developments in controlling adverse effects of interferon-based HCV treatments. The sessions took place in Barcelona from April 18 to 22, 2012. More than 7,000 clinicians and researchers participated.